IBOV 205,430.33 ▲ 0.54% IPSA 10,969.16 ▼ 0.02% IPC MEX 67,663.29 ▲ 1.31% MERVAL 2,848,932 ▼ 0.35% COLCAP 2,577.69 ▼ 0.11% BVL PERÚ 60,210.69 ▼ 0.11% USD/BRL5.07▼ 0.54% USD/MXN18.48▲ 0.36% USD/CLP984.38▲ 0.32% USD/COP3,167▼ 0.87% USD/PEN3.43▼ 0.11% USD/ARS1,518▲ 0.30% USD/UYU40.13▲ 3.08% USD/PYG5,686▲ 3.07% USD/BOB11.61▲ 2.27% USD/DOP61.26▲ 0.43% USD/CRC448.47▲ 1.59% USD/GTQ7.65▲ 3.30% USD/HNL26.86▲ 0.34% USD/NIO36.62▼ 0.07% USD/VES877.92▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 2.13% EUR/BRL5.71▲ 1.16% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 205,430.33 ▲ 0.54% IPSA 10,969.16 ▼ 0.02% IPC MEX 67,663.29 ▲ 1.31% MERVAL 2,848,932 ▼ 0.35% COLCAP 2,577.69 ▼ 0.11% BVL PERÚ 60,210.69 ▼ 0.11% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Friday, October 16, 2026

Nicaragua’s Biotech Expansion Targets Latin America and the Caribbean

By · May 24, 2024 · 2 min read

In 2014, Russia and Nicaragua founded the Latin American Institute of Biotechnology Mechnikov in Managua, signaling a new era in healthcare for Central America.

This partnership is not only aimed at enhancing healthcare but also at transforming the region’s medical infrastructure.

Quickly becoming pivotal in the health sector, Mechnikov focused on developing and producing vaccines, with an anticipated WHO certification in 2024.

This certification will allow the introduction of innovative health products throughout Central America.

Since its establishment, the institute has launched several vaccines, including Convacell, a “pancovid” vaccine effective against all COVID-19 strains.

Nicaragua's Biotech Expansion Targets Latin America and the Caribbean
Nicaragua’s Biotech Expansion Targets Latin America and the Caribbean.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

This showcases their cutting-edge approach using the stable N protein.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “IMF sees Brazil as 8th-largest economy by 2027”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

In 2019, Mechnikov marked a significant achievement by producing its first vaccine—an influenza vaccine—with more than 60 million doses produced since.

The institute now also tackles diabetes, pneumonia, and cervical cancer through its extended medical portfolio.

Significantly, in 2023, Mechnikov introduced the Cecolin vaccine against HPV, protecting Nicaraguan girls aged 9 to 14 from cervical cancer, covering over 71% of such cases.

This step is crucial for safeguarding the future health of women in the region.

Mechnikov’s Expansion Plans

As the 10-year mark approaches, Mechnikov has ambitious plans to expand its influence across Latin America and the Caribbean. It aims to introduce new products and forge technological partnerships.

Presently, it holds 24 health registrations across various countries, including El Salvador, Guatemala, and Cuba, with further expansion in progress.

Additionally, the Nicaraguan Social Security Institute plays an essential role in ensuring vaccine availability, even in crisis situations, offering more than ten times the local demand.

This capability was underscored during a major medical congress in Managua.

This story of international cooperation and technological innovation in biotechnology highlights significant strides toward a healthier future for Central America.

It demonstrates the powerful impact of global partnerships on local healthcare advancements.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.